Welcome to our dedicated page for Structure Therapeutics SEC filings (Ticker: GPCR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Structure Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Structure Therapeutics's regulatory disclosures and financial reporting.
FMR LLC, identified as a 10% owner of Structure Therapeutics Inc. (GPCR), filed a Form 4 reporting an open-market sale on 07/30/2025.
- Securities sold: 26,310 American Depositary Shares (ADS), each representing three ordinary shares.
- Sale price: $17.87 per ADS, implying cash proceeds of roughly $470 k.
- Post-sale indirect holdings: 1,515,558 ADS plus 575,934 ordinary shares (45,120 held by F-Prime Capital Partners Life Sciences Advisors Fund VI LP and 530,814 held by F-Prime Capital Partners Life Sciences Fund VI LP).
- The filing notes that Abigail P. Johnson is a director, Chairman and CEO of FMR LLC and that members of the Johnson family collectively control 49% of FMR’s voting power.
No acquisitions were reported; the sole transaction was the ADS disposition coded “S.” FMR and its affiliated funds remain above the 10% beneficial-ownership threshold.
Structure Therapeutics (GPCR) Director Russell Angus C. received a stock option grant on June 23, 2025, representing a significant insider transaction. The grant consists of 42,833 share options with the following key terms:
- Exercise price: $7.37 per share, based on fair market value of Ordinary Shares
- Vesting schedule: Equal monthly installments over 12 months from June 23, 2025
- Full vesting: Prior to 2026 annual shareholder meeting
- Expiration date: June 22, 2035
- Each ADS (American Depositary Share) represents 3 Ordinary Shares
This equity compensation grant aligns with standard director compensation practices and demonstrates long-term commitment to the company. The 10-year exercise window provides significant time value for the options.